Important Notice Regarding FDA-Approved GLP-1 Receptor Agonist Pharmaceuticals: The research-grade GLP-1 (736) amide peptide supplied by PureRawz is the endogenous native peptide and is entirely distinct from FDA-approved GLP-1 receptor agonist pharmaceutical products, including but not limited to semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), tirzepatide (Mounjaro, Zepbound), and exenatide (Byetta, Bydureon)
Users comparing liraglutide and semaglutide often note that the longer half-life of semaglutide (weekly dosing versus daily) creates a more sustained receptor activation pattern
2013;132(3):e796-809
SeekPeptides has compiled the most comprehensive storage reference available, drawing from pharmaceutical stability data, compounding pharmacy guidelines, and real-world handling experience to give you everything you need in one place
On average, patients lose about 20 to 25% of their body weight with surgery
For a complete list of side effects, please visit the Wegovy website here
